Considering the involvement of IL-6 in both the pathogenesis of IRIS and KS anti-IL-6, biological agents could be therapeutic alternatives, although clinical trials are required for the confirmation of efficiency and safety [35]. This evidence concerns the gene IL6 and Kaposi's sarcoma.